<!DOCTYPE html>
<html lang="en">
	<head>
  		<meta charset="UTF-8">
  		<title>Bio2RDF - Drugbank</title>
		<link href="images/bio2rdf.png" rel="shortcut icon" />
		<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
  		<script src="https://code.jquery.com/jquery-3.2.1.min.js"></script>
  		<script src="handlebars-v4.0.10.js"></script>
  		<!--<script src="https://cdnjs.cloudflare.com/ajax/libs/handlebars.js/4.0.10/handlebars.runtime.min.js"></script>-->
	
		<script type="application/ld+json">{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00081",
  "@type" : "Drug",
  "clinicalPharmacology" : "Tositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.",
  "cost" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:304ab26cfa3895f0e69a899b79518ff6",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "180.7700042724609375",
    "drugUnit" : "Bexxar 131 iodine dosimetric"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:1750aa01a0ce4935de1cc7f1604f5ae5",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "100.43000030517578125",
    "drugUnit" : "Bexxar 14 mg/ml dosimetric"
  } ],
  "description" : "Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).",
  "identifier" : "drugbank:DB00081",
  "interactingDrug" : [ "DDI between Tositumomab and Roflumilast - May enhance the immunosuppressive effect of Immunosuppressants.", "DDI between Tositumomab and Dicoumarol - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Tofacitinib - Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.", "DDI between Tositumomab and Belimumab - Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.", "DDI between Tositumomab and Natalizumab - Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.", "DDI between Tositumomab and Fondaparinux sodium - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Leflunomide - Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.", "DDI between Trastuzumab and Tositumomab - May enhance the neutropenic effect of Immunosuppressants.", "DDI between Tositumomab and Pimecrolimus - May enhance the adverse/toxic effect of Immunosuppressants.", "DDI between Tositumomab and Citric Acid - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Sulodexide - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Denosumab - May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.", "DDI between Tositumomab and Clozapine - Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.", "DDI between Tositumomab and Warfarin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Abciximab and Tositumomab - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Edetic Acid - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Heparin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Acenocoumarol - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Ethyl biscoumacetate - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Phenindione - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Sipuleucel-T - Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.", "DDI between Tositumomab and Phenprocoumon - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Enoxaparin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Dalteparin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.", "DDI between Tositumomab and Treprostinil - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." ],
  "legalStatus" : "Approved",
  "mechanismOfAction" : "Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation.",
  "name" : "Tositumomab",
  "nonProprietaryName" : "Ig gamma-1 chain C region",
  "proprietaryName" : "Bexxar",
  "sameAs" : [ "http://www.drugbank.ca/drugs/DB00081", "http://www.rxlist.com/cgi/generic3/bexxar.htm", "http://www.drugs.com/cdi/iodine-i-131-tositumomab.html" ],
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00081.html"
}</script>
	</head>

	<body>
		<br/><br/>
		
		<div id="all">
	 		<div id="main" style="text-align: center;">
	 			<div style="height: 20%;">&nbsp;</div>
	 			<img alt="Drugbank" src="images/drugbank.png" />
	 			<div id="main" style="text-align: center;">
	 				<em>Bio2RDF Drugbank Data</em>
				</div>

				<br/><br/>

			</div>

			<div id="contents">
				<script type="text/javascript">

				var templateCode = "<table><tbody><tr><td class='dataframeKey'>Drug Name</td><td>{{name}}</td></tr><tr><td class='dataframeKey'>Description</td><td>{{description}}</td></tr><tr><td class='dataframeKey'>Identifier</td><td>{{schema:identifier}}</td></tr><tr><td class='dataframeKey'>Non-Proprietary Names</td><td><ul>{{#each nonProprietaryName}}<li>{{this}}</li>{{else}}{{nonProprietaryName}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Proprietary Name</td><td>{{proprietaryName}}</td></tr><tr><td class='dataframeKey'>Drug Classes</td><td><ul>{{#each drugClass}}<li>{{this}}</li>{{else}}{{drugClass}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Clinical Pharmacology</td><td>{{clinicalPharmacology}}</td></tr><tr><td class='dataframeKey'>Manufacturer</td><td>{{#with manufacturer}}{{name}}{{/with}}</td></tr><tr><td class='dataframeKey'>Mechanism of Action</td><td>{{mechanismOfAction}}</td></tr><tr><td class='dataframeKey'>Food Warning</td><td>{{foodWarning}}</td></tr><tr><td class='dataframeKey'>URL</td><td><a href='{{schema:url}}'>{{schema:url}}</a></td></tr><tr><td class='dataframeKey'>Costs</td><td>{{#if cost.length}}<ul>{{#each cost}}<li>{{#with this}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}</li>{{/each}}</ul>{{else}}{{#with cost}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Available Strength</td><td>{{#if availableStrength.length}}<ul>{{#each availableStrength}}<li>{{this.description}}</li>{{/each}}</ul>{{else}}{{#with availableStrength}}{{description}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Dosage Forms</td><td><ul>{{#each dosageForm}}<li>{{this}}</li>{{else}}{{dosageForm}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Administration Route</td><td><ul>{{#each administrationRoute}}<li>{{this}}</li>{{else}}{{administrationRoute}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Interacting Drugs</td><td><ul>{{#each interactingDrug}}<li>{{this}}</li>{{else}}{{interactingDrug}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Legal Statuses</td><td><ul>{{#each legalStatus}}<li>{{this}}</li>{{else}}{{legalStatus}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Same As</td><td><ul>{{#each sameAs}}<li><a href='{{this}}'>{{this}}</a></li>{{else}}<a href='{{sameAs}}'>{{sameAs}}</a>{{/each}}</ul></td></tr></tbody></table>";
				var template = Handlebars.compile(templateCode);

				$.getJSON("jsonld/DB00081.json", function(data) {
			    	document.getElementById("contents").innerHTML += template(data);
				});
		
				</script>
			</div>
		</div>
	</body>
</html>